This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Delecluse, H. J. Articles by Berger, F. Search for Related Content PubMed PubMed Citation Articles by Delecluse, H. J. Articles by Berger, F.

American Journal of Pathology, Vol 146, 1113-1120, Copyright © 1995 by American Society for Investigative Pathology

REGULAR ARTICLES

The expression of Epstein-Barr virus latent proteins is related to the pathological features of post-transplant lymphoproliferative disorders

HJ Delecluse, E Kremmer, JP Rouault, C Cour, G Bornkamm and F Berger
Laboratory of Pathology, E. Herriot Hospital, Lyon, France.

Transplant recipients are at increased risk for the development of post- transplant lymphoproliferative disorders (PTLDs). PTLDs harbor genomes of the Epstein-Barr virus, a herpesvirus that immortalizes B cells in vitro. At least five viral proteins are required for immortalization. Two of them are particularly important. Latent membrane protein (LMP) has transforming activity in fibroblasts, and Epstein-Barr antigen (EBNA)2 transactivates the expression of numerous cellular and viral genes. To determine whether the expression of EBNA2 and LMP is related to the histological and clinical presentation of PTLD, we tested their expression in 14 Epstein-Barr virus-positive cases. Using monoclonal antibodies to EBNA2 and LMP on paraffin sections, we found an expression of both proteins in 2 of 3 polymorphic PTLD and in 7 of 8 cases of monomorphic, large cell PTLD, without plasmacytic differentiation. One polymorphic and one large cell PTLD expressed LMP only. LMP and EBNA2 were found particularly in immunoblasts. The number of positive cells was extremely variable in the different cases as well as within the same biopsy. Three cases of PTLD had morphological and phenotypical features of plasmacytomas and did not stain for EBNA2 or LMP. This suggests that the expression of EBNA2 and LMP is related to the differentiation stage of the infected cells and that other viral or cellular proteins may contribute to tumor growth.

This article has been cited by other articles:

				S. Bhaduri-McIntosh, M. J. Rotenberg, B. Gardner, M. Robert, and G. Miller Repertoire and frequency of immune cells reactive to Epstein-Barr virus-derived autologous lymphoblastoid cell lines Blood, February 1, 2008; 111(3): 1334 - 1343. [Abstract] [Full Text] [PDF]

				S. Chaganti, A. I. Bell, N. B. Pastor, A. E. Milner, M. Drayson, J. Gordon, and A. B. Rickinson Epstein-Barr virus infection in vitro can rescue germinal center B cells with inactivated immunoglobulin genes Blood, December 15, 2005; 106(13): 4249 - 4252. [Abstract] [Full Text] [PDF]

				N. H. Gudgeon, G. S. Taylor, H. M. Long, T. A. Haigh, and A. B. Rickinson Regression of Epstein-Barr Virus-Induced B-Cell Transformation In Vitro Involves Virus-Specific CD8+ T Cells as the Principal Effectors and a Novel CD4+ T-Cell Reactivity J. Virol., May 1, 2005; 79(9): 5477 - 5488. [Abstract] [Full Text] [PDF]

				M. Islas-Ohlmayer, A. Padgett-Thomas, R. Domiati-Saad, M. W. Melkus, P. D. Cravens, M. d. P. Martin, G. Netto, and J. V. Garcia Experimental Infection of NOD/SCID Mice Reconstituted with Human CD34+ Cells with Epstein-Barr Virus J. Virol., December 15, 2004; 78(24): 13891 - 13900. [Abstract] [Full Text] [PDF]

				A. Khanolkar, Z. Fu, L. J. Underwood, K. L. Bondurant, R. Rochford, and M. J. Cannon CD4+ T Cell-Induced Differentiation of EBV-Transformed Lymphoblastoid Cells Is Associated with Diminished Recognition by EBV-Specific CD8+ Cytotoxic T Cells J. Immunol., March 15, 2003; 170(6): 3187 - 3194. [Abstract] [Full Text] [PDF]

				P. Porcu, C. F. Eisenbeis, R. P. Pelletier, E. A. Davies, R. A. Baiocchi, S. Roychowdhury, S. Vourganti, G. J. Nuovo, W. L. Marsh, A. K. Ferketich, et al. Successful treatment of posttransplantation lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8+ T-cell restoration Blood, September 18, 2002; 100(7): 2341 - 2348. [Abstract] [Full Text] [PDF]

				K. L. Carter, E. Cahir-McFarland, and E. Kieff Epstein-Barr Virus-Induced Changes in B-Lymphocyte Gene Expression J. Virol., September 11, 2002; 76(20): 10427 - 10436. [Abstract] [Full Text] [PDF]

				J. M. Lee, K.-H. Lee, M. Weidner, B. A. Osborne, and S. D. Hayward Epstein-Barr virus EBNA2 blocks Nur77- mediated apoptosis PNAS, September 3, 2002; 99(18): 11878 - 11883. [Abstract] [Full Text] [PDF]

				L. J. Swinnen Post-transplant Lymphoproliferative Disorders: Implications for Acquired Immunodeficiency Syndrome-Associated Malignancies J Natl Cancer Inst Monographs, December 1, 2000; 2000(28): 38 - 43. [Abstract] [Full Text] [PDF]

				Q. Tao, L. J. Swinnen, J. Yang, G. Srivastava, K. D. Robertson, and R. F. Ambinder Methylation Status of the Epstein-Barr Virus Major Latent Promoter C in Iatrogenic B Cell Lymphoproliferative Disease : Application of PCR-Based Analysis Am. J. Pathol., August 1, 1999; 155(2): 619 - 625. [Abstract] [Full Text] [PDF]

				M. G. Horenstein, R. G. Nador, A. Chadburn, E. M. Hyjek, G. Inghirami, D. M. Knowles, and E. Cesarman Epstein-Barr Virus Latent Gene Expression in Primary Effusion Lymphomas Containing Kaposi's Sarcoma-Associated Herpesvirus/Human Herpesvirus-8 Blood, August 1, 1997; 90(3): 1186 - 1191. [Abstract] [Full Text] [PDF]